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Abstract This paper outlines some of the challenges faced by
regulation of genetic biobanking, using case studies coming
from the Italian legal system. The governance of genetic re-
sources in the context of genetic biobanks in Italy is discussed,
as an example of the stratification of different inputs and rules:
EU law, national law, orders made by authorities and soft law,
which need to be integrated with ethical principles, technolog-
ical strategies and solutions. After providing an overview of the
Italian legal regulation of genetic data processing, it considers
the fate of genetic material and IP rights in the event of a
biobank’s insolvency. To this end, it analyses two case studies:
a controversial bankruptcy case which occurred in Sardinia, one
of the first examples of private and public partnership biobanks.
Another case study considered is the Chris project: an example
of partnership between a research institute in Bolzano and the
South Tyrolean Health System. Both cases seem to point in the
same direction, suggesting expediency of promoting and im-
proving public-private partnerships to manage biological tis-
sues and biotrust to conciliate patent law and public interest.
Keywords Biobanking . Genetic data . Informed consent .
Gene patent . Data protection . Privacy . Bankruptcy .General
Data Protection Regulation . Italian law
Introduction
The relationship between law, science and technology is a mul-
tifaceted interaction, which has increased in complexity over
the last 20 years (Rodotà 1995; Jasanoff 1995; Brownsword
2008). Advances in bioinformatics and genomics and the pos-
sibility of access to several networks, infrastructures, and data-
bases have reshaped our notions of doing biomedical research
on the one hand (Trinidad et al. 2010) and on informational risk
on the other, leading to the idea that anonymity in research may
well be a chimera (Kaye 2012). The attempt to regulate research
in genomics and biobank activities has impacted heavily on
traditional legal concepts and categories such as property, pri-
vacy and informed consent (Kaye 2012; Kaye et al. 2015).
The studies of population genomics aim at understanding
human health and gene environment interaction in the develop-
ment of diseases, with the long-term goal of helping the discov-
ery of targeted diagnostics and therapies. In order to achieve
this objective, there is a need for large-scale collection of data
on phenotypic traits (health data, lifestyle, behaviours) andwide
availability of genomic data to carry out research into genetic
variability and gene environment interaction across whole pop-
ulations (Kaye et al. 2009; Mascalzoni et al. 2014a; Knoppers
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and Abdul-Rahman 2008). For these purposes, population
biobanks have become a necessary infrastructure basis for life
science innovation on an international basis and the recipient of
considerable funding. The governance of biological materials
and related data stored in genetic biobanks depends on the
typology of the biobanks, on the anticipated use (different rules
apply to the collections of biosamples used in different settings,
as for instance in a clinical setting or for research, from patients
or healthy individuals), on legal frameworks where nationally
and internationally binding and non-binding rules apply and,
last but not least, on the limits set by consent and agreements
with individuals and groups.
As defined by the Council of Europe (2006), population
biobanks are collections of human biological materials on a
population basis derived from or destined for research pro-
jects, which contain “biological materials and associate per-
sonal data, which may include or be linked to genealogical,
medical and lifestyle data and which may be regularly up-
dated”. The large amount of samples and data required to
achieve statistical significance has led, in the past decade, to
a great increase in national and international biobanking cre-
ation, both commercial and public. Another phenomenon
which has posed a great challenge to local and international
regulation is the rise of worldwide consortia (GIANT, Rd-
Connect, BioSHaRE, just to name a few) (Knoppers et al.
2011) aiming at information sharing (Budin-Ljosne et al.
2014) and at adopting common operating procedures, includ-
ing approaches to ethical and legal requirements (Knoppers
et al. 2014), such as consent (Gainotti et al. 2016), data pro-
tection (Budin-Ljosne et al. 2015) and privacy. Biological
samples are collected from participants or patients, whose in-
formed consent is needed for storage and use in genetic inves-
tigation, retaining an interest in the biomaterials and in the
associated data. It is therefore controversial to apply tradition-
al legal categories, such as “property” (Tallacchini 2005;
Yassin et al. 2010) to determine the interests associated with
biosamples, genetic data and the protection of research results
linked to proprietary interests such as intellectual property or
patents. Therefore, such traditional categories run the risk of
being inadequate and new definitions, or at least new interpre-
tations, are needed.
In setting up and formalizing networks of collection, storage
and exchange of biomaterials and genetic data, biobanking ac-
tivity has become a noteworthy example of the controversial
relationship between research institutions and civil society, feed-
ing into the wider debate on the oversight, governance, supervi-
sion and accountability of biological innovation. Indeed, the
legal regulation of genetics biobanks is at the centre of different
disciplines and opposing interests that need to be balanced.
One of the most controversial issues concerns the legal
nature of the subject-matter of the biobanking activity, i.e.
the biological sample (Macilotti 2013). The latter is a “res”,
a tangible good, which traditionally attracts the category of
property rights. At the same time, it is the carrier of genetic
information that relates to the person who has donated that
biological material. Furthermore, such information presents
a challenging scenario, because its processing is likely to af-
fect persons other than the data subject, namely his/her rela-
tives and the whole biological family (Rodotà 2006). Groups
and individuals, in fact, are linked by genetic information,
even if they ignore their reciprocal family bonds, thus framing
privacy in a new way (Mascalzoni et al. 2014b). It is therefore
crucial that research activity is carried out taking into account
the rights and the dignity of all subjects involved.
With regard to patients and research participants, genetics
holds new implications for informed consent procedures. On
the one hand, it allows for new possibilities but, on the other, it
raises critical issues, such as the right to know or not to know,
the right to obtain only partial information with appropriate
counselling, the right to control the use of samples for a spe-
cific study, excluding other aims or investigations and the
problems surrounding the return of incidental findings, family
implications, international use and secondary uses of data
(Burke et al. 2013; Budin-Ljosne et al. 2017).
Another critical point concerns the balancing between, on
one side, property and intellectual property rights over biolog-
ical collections and publications/inventions derived from them
and, on the other, the public interest, i.e. the societal right to
benefit from scientific progress.
Such competing demands illustrate the complexity of
governing genetic biobanks and of drawing a line between
public and private interests in this field. Here, public trust
and civic engagement are particularly important issues, also
bearing in mind the future-oriented features of this infrastruc-
ture which requires consensus on the governance of biological
material deposited for future use and in the hands of brokers or
an intermediary (often the biobank itself) supplying
biospecimens to different researchers (Rothstein 2005) for
different projects.
To manage controversial issues around the storage of bio-
logical materials of human origin, the Council of Europe has
adopted recommendations (2016) oriented to “protect the dig-
nity and identity of all human beings and guarantee everyone,
without discrimination, respect for their integrity, the right to
respect for private life and other rights and fundamental free-
doms”. This updated version also contemplates provisions
concerning the termination of a collection of biological mate-
rials: while it does foresee the possibility of giving consent for
future uses, it suggests well-designed guidance to balance this
freedomwith the protection of individual rights, indicating the
necessity for governance by the institution with the custodi-
anship of the biomaterials, as well as clear rules for the access,
sharing, and management of biosamples. Third party external
review of projects carried out on biomaterials is required, as
well as clear indications on possible return of results in general
and on an individual level. Unexpected or planned closure, for
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instance depending from funding availability or bankrupt, in
fact, raises important ethical, legal and social questions about
the fate of stored biological materials and data, concerning the
prospect of preserving, destroying or transferring them to oth-
er entities and, in this latter case, the transfer criteria, including
the participants’ consent (Zawati et al. 2011). This issue has,
over time, been a neglected aspect of biobanking regulation.
This paper will consider some of the gaps left by the inter-
play of different regulations that have led to paradigmatic
examples in the Italian legal framework. In particular, we will
consider the fate of genetic material in the event of insolvency
of biobank and biobanks governance, as the outcome of a
complex regulatory framework.
The first part provides an overview of the Italian legal regu-
lation of genetic data processing, taking into account the entry
into force of the new EU GDPR (General Data Protection
Regulation), which seems to be research oriented and provides
an opportunity to reach a fair balance between individual rights
and research freedom, while the Italian regulation focuses on
individual rights. The role of the data protection authority is
taken into due account, providing a more flexible solution than
the discipline left only to statutory law, which is the approach
generally taken by civil law countries, such as Italy.
After this general outline, the article considers the fate of
genetic material and IP rights in case of insolvency of
biobanks’ and biobank governance as the outcome of a com-
plex regulatory framework.
To this aim, we provide two case studies.
The first occurred in Sardinia and deals with the controver-
sial bankruptcy case of one of the first examples of private and
public partnership biobanks. This case offers the opportunity
to analyse the special characteristics of biological samples,
which are not to be regulated as “res” according to a traditional
sense of the civil law. These characteristics have been ad-
dressed by the Italian data protection authority, which adopted
some decisions blocking the processing of the biobank data.
The paper considers different options to manage bankruptcy:
in particular, it invites to consider the biological tissues as
commons to be owned by a public biobank or, as an alterna-
tive, to be managed according to new kind of partnerships
which allow a balance between commercial purposes, the re-
spect of participants, and the public interest.
Finally, we provide for a second case study, the Chris pro-
ject, as an example of partnership between a research institute
in Bolzano and the South Tyrolean Health System, which
aims at guaranteeing the interaction between researchers and
the local population and to ensure that in any event there is a
public funding responsibility to sustain the project which in-
volves the local population.
We suggest that, while some changes in the regulations
could account for resolving some of these cases, others could
be covered only by a well-structured collaboration between
law, governance and self-regulation. In fact, while the legal
landscape alone sometimes does not provide satisfactory an-
swers, alternative governance models that use mixed models
(including self-regulation) can offer possible flexible
solutions.
The Italian regulatory framework on genetic data
processing and the impact of the General Data Protection
Regulation: balancing interests?
The processing of genetic data in Italy is governed by a regu-
lation that is, in many respects, stricter than those existing in
other EU Countries. This situation will most likely change,
with the entry into force of the new EU GDPR. This act,
approved in May 2016, will repeal Directive 95/46/EC with
effect from 25 May 2018: this two-year period will allow
Member States to revise or adapt their legislation in order to
comply with the GDPR. This shift in paradigm from a
Directive (setting certain aims to be achieved) to a
Regulation (setting specific rules to be complied with) can
be referred to as a ‘harmonization through adaptation’ process
(de Hert and Papakonstantinou 2016). The Regulation offers
renewed focus on the protection of “sensitive data”, including
both health and genetic data, and on research taking advantage
of information from registries, which “can provide solid, high-
quality knowledge which can provide the basis for the formu-
lation and implementation of knowledge-based policy, im-
prove the quality of life for a number of people and improve
the efficiency of social services” (Recital 157).
For the sake of clarity, the level of harmonization pursued
by means of the Regulation, is actually an “incomplete” one.
Article 9.4. of the GDPR, in fact, allows Member States to
“maintain or introduce further conditions, including limita-
tions, with regard to the processing of genetic data, biometric
data or data concerning health”. This allowsMember States to
introduce further appropriate and possibly differentiated safe-
guards for the rights and freedoms of the data subject.
Traces of the attention paid by the GDPR to scientific re-
search and biobanking activities, although not fully clear, can
be read in different provisions.
First, from the general viewpoint of the scope of the
Regulation, with regard to the functioning of biobanks, Art.
4(3b) introduces a definition of “pseudonymisation”, which is
defined as “the processing of personal data in such a manner
that the personal data can no longer be attributed to a specific
data subject without the use of additional information, provid-
ed that such additional information is kept separately and is
subject to technical and organisational measures to ensure that
the personal data are not attributed to an identified or identifi-
able natural person” (Article 4(5)). Recital 26 states that
Personal data which have undergone pseudonymisation, being
attributed to a natural person by the use of additional informa-
tion, should be considered to be information on an identifiable
natural person and fall within the scope of the Regulation.
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Nonetheless, the scope of identifiability is qualified by the
reference to “means reasonably likely to be used”: therefore,
there may be cases where pseudonymised data, together with a
combination of organisational, legal and technological mea-
sures, can be considered anonymous data (Knoppers and
Saginur 2005; Wjst 2010; Bolognini and Bistolfi 2017).
This is still a matter to be clarified and, along with other
questions related to data for research, is under discussion by
different groups comprised of researchers, policy makers and
patients’ group representatives which, as provided for under
the GDPR, will propose a code of Conduct for research to the
commission, an effort lead by the BBMRI ERIC (http://www.
bbmri-eric.eu/bbmri-eric/).
Secondly, the new Regulation recognizes that it is often
impossible to fully identify the purpose of personal data pro-
cessing for scientific research purposes at the time of data
collection. Therefore, in keeping with recognized ethical stan-
dards, data subjects should be allowed to give their consent to
certain areas of scientific research. In a departure from the
1995Directive, where consent provisions were often narrowly
interpreted, Recital 33 creates an opportunity to bring consent
closer to a broad consent model, currently employed in the
research practice by some Member States. The possibility of
consenting to “certain areas of scientific research” allows de-
tachment from an informed consent clearly tailored to a spe-
cific research project.
Another aspect, which once again stresses the favour
shown to research, is related to secondary uses. Generally
speaking, the Regulation prevents personal data collected for
one purpose being used for another incompatible purpose.
However, some provisions explain that further processing
for scientific research, statistical or historical purposes can
be considered “not incompatible” purposes. In order to benefit
from this presumption specific safeguards must be fulfilled
(Safeguards are set out in Article 89 and Recital 156, as well
as in Article 9, when data concerning health is processed).
The awareness and trust towards research and biobanking
shown by the GDPR marks the most evident general differ-
ence between the Italian discipline on these issues and the EU
approach. It is important to highlight that the current version
of the GDPR is the result of negotiations and the first draft was
very strict regarding secondary uses.
In Italy, the regulation on the processing of genetic data has
been left to the Italian Data Protection Authority (IDPA)
which places great emphasis on individual rights. The Italian
legislator, when reorganising the whole discipline of privacy,
decided to refer to an independent administrative authority for
the identification of rules for regulating the processing of ge-
netic data. According to Art. 90 of the Italian Data Protection
Code (Legislative Decree no. 196 of 30 June 2003, IDPC) the
processing of genetic data, regardless of the entity processing
them, is allowed exclusively in the cases provided for in ad-
hoc authorisations granted by the IDPA in agreement with the
Minister for Health and the Istituto Superiore di Sanità
[Higher Health Care Council]. Genetic data is thus considered
as “hyper” sensitive information, subject to a special set of
rules (the possibility of using and disseminating personal data
for research purposes is regulated by another Authorization
(no. 9/2016) which explicitly excludes genetic data from its
scope), provided by the General Authorization for the
Processing of Genetic Data (no. 8/2016). This document pro-
vides for general principles (also involving themanagement of
biological samples—solely considered as a source of informa-
tion) concerning the purposes of use, requirements (i.e. con-
sent), storage and communication.
Although scientific research is explicitly recognised as a
legitimate purpose for the processing of genetic data (upon
consent given by the data subject), the lack of specific provi-
sions for certain types of research activities is easily
identifiable.
A couple of examples will clarify the point. With regard to
informed consent, the General Authorization states that “ge-
netic data may be processed and biological samples used ex-
clusively for the purposes specified herein, on condition the
person concerned has provided his/her written informed con-
sent thereto” and “information notices shall include (…) a
detailed list of all the specific purposes to be achieved”
(Points 5 and 6). This provision clearly disregards the possi-
bility of developing research tracks following further pur-
poses, not fully identifiable at the time of data collection.
Furthermore, the processing of genetic data for purposes other
than those for which the personal data were initially collected
is only possible where the scientific and statistical purposes
are related directly to those for which the data subjects’ in-
formed consent had been obtained initially. Samples and data
can be used only for different research projects (without re-
consent), in cases where the data subjects can no longer be
identified or if, despite all reasonable efforts, it is impossible to
contact the data subject and the research program has been
specifically authorized by the IDPA and given a favourable
opinion by an ethics committee (Point 8). As always, one
solution does not fit all. Re-contact is a very sensitive issue,
as it is costly and burdensome, and needs to be pursued only
when necessary, but when necessary should be pursued (Black
et al. 2013; Green et al. 2013; Budin-Ljosne et al. 2017;
Budin-Ljosne et al. 2011; Gainotti et al. 2016; McCormack
et al. 2016).
This quite strict framework, not supported by any provision
on how re-consent can be obtained easily, is further completed
by the provis ion on “Data Communica t ion and
Dissemination” (Paragraph 9), which can be divided into
two parts. Under the first, “Genetic data may not be commu-
nicated and biological samples may not be made available to
third parties unless this is indispensable for the purposes men-
tioned herein” or under specific contracts that ensure the same
degree of security under the data controller. The method of
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“communicating” data may concern the possibility of working
on joint projects together with other research institutions, pos-
sible only through complex Data Transfer Agreements.
Moreover, unidentifiable data can be communicated for the
pursue of directly related aims, but no communication or
transfer to third parties is generally allowed. The second part
of this paragraph states: “[n]o genetic data may be disseminat-
ed. Research findingsmay only be disseminated as aggregated
information, or in accordance with such arrangements that can
prevent data subjects from being identified also by way of
indirect identification data; this shall also apply to publica-
tions”. Even consent seems incapable of overcoming this
broad and general prohibition, considering that—where
deemed feasible—other points of the Authorization explicitly
refer to individual consent as a way of lifting restrictive pro-
hibitions. Besides seriously hampering the possibility of shar-
ing individual research data (in particular on public accessible
genetic databases), this provision, taken together with others,
demonstrates the precautionary attitude of the whole Italian
regulatory framework regarding the processing of genetic
data.
Time will tell how the Italian legal system will confront the
opportunity offered by the GDPR, and if it will in some way
take advantage of the “partial” harmonization strategy allowed
by the EU, introducing higher standards of protection for the
individual and thus modifying the balance struck by the
Regulation.
Understanding this background is a necessary precursor for
correctly identifying and contextualizing the case studies that
will be described in this paper.
The problem with a strict law where complexities are in-
completely grasped is that in some cases it may end up ham-
pering scientific research without fulfilling its purpose:
protecting individuals, as highlighted in the first case.
Case study n. 1: the Sardinia case
Sardinia is the second biggest island of Italy, located right in
the middle of the Tyrrhenian Sea. In some of its areas, geo-
graphical isolation and historical factors resulted in develop-
ment of genetically homogenous populations. Talana village
in the central-eastern Ogliastra area, for instance, was
established a thousand years ago by a remarkably small num-
ber of original settlers. Among the 1200 inhabitants who were
the subjects of a census at the beginning of 2000, 75%
descended from 8 founder fathers and 10 founder mothers,
and 95% of marriages involved spouses of the same village,
35% even consanguineous. Moreover, church records enable
families to be traced back to the 17th century (Meldolesi
2000). This population can rightly be regarded as a genetic
isolate, characterized by a homogeneous genetic background
and therefore suitable for analysing the genome-environment
and lifestyle interaction. Because of antiquity, slow
demographic growth, isolation and high degree of endogamy
and consanguinity, i.e. the most amenable features for genetic
population studies, Sardinia (with particular focus on its iso-
lated areas) has since the middle of 1990s been an ideal re-
search location for accomplishing genetic population studies
aimed at identifying multifactorial genetic traits with potential
biomedical interest. Among these features longevity, since
Sardinia has been designated a “Blue Zone”, i.e. a location
with the highest numbers of centenarians in the world (Poulain
et al. 2004). Substantial projects and ventures were developed.
Worth mentioning is one of the first research studies carried
out in the Ogliastra area, the multidisciplinary AKEntAnnos
project by the Institute of Population Genetics of the Italian
National Research Council (IGP-CNR), aimed at identifying
genes predisposing to multifactorial diseases and to complex
traits, under the epidemiological, genealogical, genetic, mo-
lecular and statistical profiles (Deiana et al. 1999). To unravel
the genetic processes involved in age-related traits and dis-
eases, the Italian National Research Council (CNR) Institute
of Cagliari and the US National Institute on Ageing (NIA)
carried out the SardiNIA project, also called ‘Progenia’ for
the Sardinian public (https://sardinia.nia.nih.gov/).
In 2000, the “genetic exceptionalism” of the Ogliastra re-
gion also facilitated the creation of one of the first Italian
public and private partnerships in genomics: Shardna.
Founded as an Italian S.r.l. (limited company), Shardna soon
attracted various investors, both from the private and the pub-
lic sector. The Shardna project aimed at establishing a primary
resource for identifying genes for complex diseases, such as
hypertension, kidney stones, migraines, obesity, eye diseases
and hair loss (Meldolesi 2000), involving 10 villages of the
mountainous region of Ogliastra (Baunei, Escalaplano,
Loceri, Perdasdefogu, Seui, Seulo, Ussassai, Urzulei, Talana
and Triei). A critical mass of biological samples from 11,700
individuals was collected, giving rise to a genetic biobank,
publications (complete list available at http://web.tiscali.it/
shardna) and patents. Inspired by a forward-looking vision,
research was carried out during the whole project in close
collaboration with the local communities, generating a virtu-
ous circle of participation based on informative meetings, a
careful design of truly informed consent and constant contact
with field staff and researchers. A laboratory and a small clinic
were set up in the selected villages, and as a benefit, partici-
pants could receive individual feedback on the genetic analy-
sis and free medical check-ups (Artizzu 2008). This latter was
an appealing motivation since the nearest hospital was located
an hour away from most of the villages in the Ogliastra dis-
trict. Thanks to this active engagement of the population and
the constant information provided in loco by the researchers,
the percentage of volunteers was very high, surpassing 80%
(Artizzu 2008).
Nearly 10 years after its creation, a transition occurred at
the top of Shardna company, giving rise to a controversial
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bankruptcy case, which is worth analysing as a case study for
its weight of social, legal and ethical implications. In 2009, the
majority shareholder sold his shares for 3,000,000 Euros to
the Fondazione San Raffaele, a prestigious Italian foundation
involved in scientific and medical research and health and
charitable activities. In 2011, however, the San Raffaele
Foundation was hit by a financial crisis and forced to start a
procedure of arrangement with creditors (in Italian
“concordato preventivo”), opening the door to the bargain sale
of Shardna by a bankruptcy court in 2012 (see the decree of
the Tribunal ofMilan at: http://www.sanraffaele.org/static/upl/
de/decretoomologa10-05-2012.pdf). After years of silence
about the outcome of the procedure, finally in July 2016 the
media (see for instance: ANSA 2016; The Guardian 2016)
spread the news on the purchase of Shardna by Tiziana Life
Sciences Plc, a UK biotechnology company (http://www.
tizianalifesciences.com/Welcome_to_Tiziana.html). Tiziana
Life Sciences created Longevia genomics Srl, an Italian
subsidiary, in order to assign the Shardna assets. Despite an
estimate value of 3,000,000.00 Euros, Tiziana Life has finally
bought it for just 258,000.00 Euros. The bankrupt assets
include the right to use the biological samples plus the
clinical documentation; the declarations of consent of the
participants; the equipment and the content of the biobank;
the database comprising the medical histories of the donors.
The declared goals of the newborn company are to continue
the Shardna project as well as to start its own new research
activities (Italian Data Protection Authority, Provvedimento di
blocco del trattamento dei dati personali contenuti in una
biobanca, 06.10.2016).
The events surrounding Shardna’s bankruptcy have reso-
nated beyond Italy, being the subject of a Parliamentary ques-
tion to the Commission in July–August 2016 (see Question
for written answer to the Commission by Giulia Moi (EFDD),
P-005318-16 and the answer given by Ms. Jourová on behalf
of the Commission, 25 August 2016, P-005318/2016). They
have also been followed with great attention by the Italian
Data Protection Authority (IDPA). As recognized under
Italian law, the relevant case law (for instance, the case S.
and Marper v UK decided by the European Court of Human
Rights), and the new General Data Protection Regulation,
biological samples share a common ground with personal
data. Indeed, biological samples are the tangible
manifestation of an informational content: they are the
carrier of personal information, which is ontologically
embedded in them. In other words, biological samples are
able to reveal information which refers to an identified or
identifiable person. For this reason, they deserve the same
level of protection reserved to personal data.
As a consequence, the biobank transfer should be guided
by the relevant applicable provisions concerning data protec-
tion: personal data must be processed fairly and lawfully, col-
lected for specified, explicit and legitimate purposes, not be
further processed in a way incompatible with those purposes
and not kept longer than necessary for those purposes. In
particular, Article 16 of the IDPC (Legislative Decree 196/
2003) contains a specific provision concerning the issue at
stake. It establishes that, in the event of processing termina-
tion, for whatever reason, the data shall be alternatively: (a)
destroyed; (b) assigned to another data controller, provided
they are intended for processing under terms that are compat-
ible with the purposes for which the data have been collected;
(c) kept for exclusively personal purposes, without being
intended for systematic communication or dissemination; or
(d) kept or assigned to another controller for historical, scien-
tific or statistical purposes, in compliance with laws, regula-
tions, Community legislation and the codes of conduct and
professional practice. However, this provision has to be coor-
dinated with the above-mentioned General Authorization for
the Processing of Genetic Data (no. 8/2016) which allows the
transfer of biological samples to third parties (not involved in
joint projects) only where certain conditions are met (see the
previous paragraph).
With reference to the Shardna events, over the last few
years the IDPA has received hundreds of donors’ complaints,
alleging in particular the lack of information regarding the
conservation period of genetic data and biological samples;
the role of Parco Gen.O.S. in the processing and the identity
of the data controller of the biobank (see IDPA,
Provvedimento di blocco del trattamento dei dati personali
contenuti in una biobanca, 06.10.2016). Furthermore, com-
plaints also concerned with unlawful collection of personal
data from the municipal data archive, the lack of appropriate
security measures, and the inability of donors to exercise their
rights (for instance, the withdrawal of consent and the right to
consent to the processing performed by the new data
controller).
On the basis of a preliminary assessment, the Authority has
considered that Tiziana Life Sciences aims to undertake pro-
cessing compatible with the purposes for which personal data
were originally collected. However, according to the IDPA,
“the facts present some critical issues with regard to certain
aspects of the processing” (Italian Data Protection Authority,
Provvedimento di blocco del trattamento dei dati personali
contenuti in una biobanca, 06.10.2016). For this reason,
pending completion of the Authority’s investigation, with
Decision 389 taken at the beginning of October 2016, our
national data protection Authority has established the imme-
diate blocking of the processing of the biobank data. This
means that Tiziana Life Sciences must refrain from any further
processing of data and biological samples, apart from ensuring
the appropriate storage of the latter; re-contacting data sub-
jects to provide information and acquire new consent; provid-
ing adequate responses to data subjects who want to exercise
their rights. Therefore, it is expected that the coming months
will be crucial for the fate of the Sardinian biobank.
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… and its legal consequences: what happens in case
of insolvency of biobank? A private-public perspective
In the Italian legal order, the problems underlying the
treatment of genetic material, and especially the protec-
tion of genetic information increase in the context of the
crisis of a company and of its subsequent bankruptcy. The
reason for this difficulty lies in the absence of a unitary
legislation precisely regulating the limitations of the use
of genetic material and identifying its owner, once the
genetic material is separated from the source subject.
Last but not least, a further problem lies in the classifica-
tion of a biobank and, especially in the case of bankrupt-
cy, in the relation existing between the classification and
the type of company or the legal system.
The bankruptcy of the Sardinian company, previously
mentioned, gave us the opportunity to think about the
legal fate of genetic material in case of the insolvency
of biobanks and, in particular, the possibility of forming
the subject-matter of a bankruptcy sale. According to the
Italian regulation which is, as stated above, quite incom-
plete on this point and, according to the majority of legal
scholars, in the event that the genetic material could not
be transferred, in particular because of the lack of specific
authorization given by participants to the biobank.
Despite this, the official receiver has not only handled
the data base sale (including all the genetic data collected
over years), but has also handled the numerous blood test-
tubes protected in cold storage (refrigerating rooms).
This decision caused public controversy regarding the of-
ficial receiver’s powers in the bankruptcy centre and deter-
mined two different actions. They have been respectively un-
dertaken, the first one before a Court, for the suspension of the
bankruptcy sale, and it has not yet been determined, and the
other on the administrative side before the IDPA for the sus-
pension of the processing of personal data.
What are the decisional powers held by Administrator
following the failure of the company holding the biobank
and, particularly, as regards liquidation of the company
assets?
The Italian bankruptcy law, in sections of Art. 104 and s.
1. which regulates the procedure of liquidation of social
assets after bankruptcy, states that the official receiver
has to use every competitive method in the sales operations
so that he/she can sell the assets of the company to the
highest bidder (Vassalli et al. 2014). This means that ac-
cording to the Italian bankruptcy law there are no require-
ments placed on buyers in relation to the property sold;
likewise, it is not possible to know how this property will
be used once sold. In other words, the official receiver
cannot favour any buyer: this means that the material could
be sold to entities who pursue a (even partially) different
purpose, not only from that of the biobank, but also from
the purpose which the donor had authorized in the consent
form (Zawati et al. 2011; Carroll 2002, Janger 2005).
In this specific case, indeed, the official receiver, aware of
the necessity of finding a specialised buyer through focused
search, decided that the winning bidder should, as the main
object of his/her activity, have conducted research activity in
the genetic-medical field.
Therefore, how has the need for the donor’s authorisation
been set alongside the gap in the Italian legal order in case of
bankruptcy of a company which holds genetic material? First
of all, the collected and catalogued genetic material should be
considered as a vehicle for both personal information and
potential public interest in pursuing the research aim. In this
case, the whole set of EU rules concerning the protection of
sensitive data and the management of biological samples may
be applied. Specifically, the official receiver should be bound-
ed by Article 16 IDPC and, in particular, by the obligation to
assign the data to another data controller only if they are
intended for processing under terms that are compatible with
the purposes for which the data have been collected or for
historical, scientific or statistical purposes. In this way, the
official receiver has to choose potential buyers who will be
able to adhere to the scientific aim of the research. This use
should be in compliance with the indication contained in the
consents given by participants, unless new consent can be
obtained. In case a correspondence is not found and re-
consent is not obtained, the “extrema ratio” would be the
destruction of the collected samples. However, this solution
would not be workable for at least two reasons: first, because
this would harm the bankruptcy assets; secondly, because it
would destroy a valuable resource which could be further
exploited for research purposes. To avoid this event, appropri-
ate consent forms are required, where the patient can expressly
decide about the transfer of the biological material to the
biobank to pursue a specific scientific aim, even in case of
company failure or bankruptcy. Nevertheless, there is no evi-
dence that, in the Sardinian case described, any authorization
was given. If this were the case, this situation might compli-
cate the bankruptcy sale and the pursuit of the research: in-
deed, the winning bidder could not have any legitimacy in
maintaining the research activity.
A different option in managing biological materials in the
event of liquidation/failure of a biobank, could be found by
considering human tissues as commons, therefore enhancing
the value of the information contained in the biological sam-
ple, and transforming the sample itself into an asset, which can
be identified by a court. If we accept that perspective, it would
be necessary to identify an entity or a recognised organisation
able to guarantee both the nature of the biological samples as
commons and the respect of the aim of the research through
their proper use. This entity could be a public institution, spe-
cifically an entirely publicly owned biobank which keeps the
tissues and the information, sharing the samples with the
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researchers who ask for them. In this perspective, the publicly
owned biobank would function not only as a guarantor of
privacy and as a protector of the scientific research, but it
would also be free from any risk regarding bankruptcy events,
not being the type of business entity subject to such risk.
The acceptance, in civil law legal systems as well, of the
model of a charitable trust (biotrust) would be an interesting
development, in order to regulate the functioning of biobanks,
with clear governance available for scrutiny of participants at
the time of the collection, where individuals could assess
whether they may trust the model for access, sharing and
managing contact, re-contact etc. (Winickoff and Winickoff
2003). The structure of this model would, on the one hand, be
able to monitor the observance of the duties of the researchers
and, on the other, to promote the engagement of the partici-
pants in the biobank in the management of scientific research.
Additionally, one-time consent seems obsolete, in an era of
fast development and the nature of research, which changes
day by day.
All in all, many of the problems dealt in this paragraph
could be easily solved through the precautionary choice of a
form of association which is not subject to insolvency proce-
dures and by ensuring transparent information at the time of
decision making.
The patentability of human genes in the framework
of European and Italian regulation
The patentability of human genes is another interesting topic
to provide an analysis of the social implications of public-
private initiatives in the field of genetics.
Both a direct and indirect commercial value is associated
with biological samples, information about sample donors and
inventions resulting from research with samples and associat-
ed data. Directly, through the patenting, under certain condi-
tions, of DNA sequences; indirectly, where the study of ag-
gregate samples results in the development of new medicines
and personalized care techniques.
The economic value of genetic resources corresponds to
how they are assessed as potential sources of profit, represent-
ed by the utility, applicability and reproducibility within the
market of chemical and biological information which such
resources contain. Information deriving from biological diver-
sity, once elaborated in the research and development phase,
acts, in turn, as a basis for new products and, therefore, can be
considered a double resource: a resource “per se”, and a new
primer for innovative research. Nevertheless, conflicting inter-
ests between freedom of scientific research and access to sci-
entific knowledge are now arising, requiring a more careful
equilibrium between the public and the private domain
(Reichman et al., 2016).
Currently, in Europe, the legal protection of biotechnolog-
ical inventions involving genetic material is ensured by the
framework of Directive 98/44/EC (Directive 98/44/EC of
the European Parliament and of the Council of 6 July 1998
on the legal protection of biotechnological inventions (GUCE,
L 213 of 30 July 1998)) and the European Patent Convention
(EPC). On the other hand, the international discipline of pat-
ents is represented by the Agreement on Trade-Related
Aspects of Intellectual Property Rights (TRIPs 1994). The
TRIPs Agreement sets minimum standards that member
States must comply with when regulating IPRs in their domes-
tic systems. In the majority of the European Union member
states, the provisions of Directive 98/44/EC have been includ-
ed within different national laws regulating patents. As
regards Italy, the directive’s content has been included in the
Industrial Property Code within Legislative decree no. 131 of
2010.
The Italian legislation (Industrial Property Code,
Legislative decree, n. 30 of 10 February 2005) provides
the patentability of an invention relating to an isolated
element of the human body or otherwise produced by
means of a technical process, even if its structure is iden-
tical to that of a natural element (Art. 81-quater lett. d)
industrial property code, in accordance with Arts. 3, 4, 5.2
dir. 98/44/EC); in particular, when the biotechnological
patent concerns genes or sequences of genes, there is an
obligation to indicate and specifically describe its function
and industrial pertinence in the patent description and in
the claims of the patent application.
In addition, according to Article 170-bis, paragraph 3, of
the Italian Industrial Property Code, “a patent application re-
lating to an invention whose object is, or that utilizes, biolog-
ical material of human origin, must be accompanied by the
express, free and informed consent, for that sample and utili-
zation, of the person fromwhom the material was taken, based
on applicable legislation” (see Article 170-bis of the Italian
Industrial Property Code, and Article 22.5 of the
Implementing Regulation of the Italian Industrial Property
Code) (Rovati 2016).
The aforementioned provision must be read in conjunction
with three further provisions: article 22, paragraph 5, of the
Implementing Regulation of the Italian Industrial Property
Code, and articles 170-bis, paragraph 7, and 173, paragraph 7,
of the Italian Industrial Property Code. The following conclu-
sion can be drawn from a thorough reading of such provisions:
(i) the patent applicant must attach the statement of consent to
the patent application; (ii) the consent must concern both the
sample-taking and the subsequent use of the biological sam-
ple; (iii) where the statement of consent has not been attached,
the Italian Patent and Trademark Office (UIBM) sets a date for
integrations and further observations, and only if the office
feels it cannot accept these observations it rejects the applica-
tion. Finally article 170-bis does not seem to address whether
the statement of consent should cover only the commercial
use or even use for experimental purposes.
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However, the patent system does not deal directly with the
issue of consent acquisition to the sample-taking and of the
use of data and biological material; this profile is in fact reg-
ulated by different legislation and based on various interna-
tional and constitutional rules (see Art. 3.2 Charter of
fundamental rights of the European Union; arts. 2, 13, 32
Italian Constitution; Arts. 16 and 22, Oviedo Convention on
Human Rights and Biomedicine; Arts. 6 and 8 International
Declaration on Human Genetic Data 2003. See also
Romandini 2007).
Furthemore, we have to take into account that a biobank is
constituted of an organized collection of biological material
(such as samples of blood, blood serum, plasma, DNA) and
corresponding database containing data and information relat-
ed to the samples (and the donors). In this sense, it has been
widely debated whether the biobank (as collection of biolog-
ical samples) may be considered as a database (Bygrave 2012)
and, in this latter case, whether it is eligible for protection
under copyright laws or the sui generis right. Under
European and Italian Law, a collection of works, data and
other materials can be defined database when it is: (i) inde-
pendent; (ii) systematically or methodically arranged; (iii) in-
dividually accessible. If the above-mentioned requirements
are met, and provided that the database is creative, then copy-
right protection is granted; on the contrary, if the requisite of
creativity lacks, but the creation of the database has required a
substantial economic investment, it is entitled to the sui
generis rights protection. The evaluation of the level of orig-
inality of the biobank database must be done in a case-by-case
basis. However, considering the object of the activity of a
biobank, it will be probably hard to configure its database as
an original one. Indeed, for the purpose of collection and
study, the selection and arrangement of the contents is gener-
ally a trivial one: samples and data are arranged according to
pathology, put in a chronological/alphabetic order, etc. On the
contrary, if there is a substantial investment in either the
obtaining, verification or presentation of the contents, the
maker of the database can enjoy the sui generis right protec-
tion. However, the application of this kind of protection to the
specific context of biobank is still controversial (Ducato
2013).
What is the fate of the intellectual property rights owned by
the biobank if it goes bankrupt? As regards such rights, these
are freely transferable by contract, either definitively or tem-
porarily. In fact, and in the event of bankruptcy, these econom-
ic rights become part of the entire pool of the company’s assets
(Maffei-Alberti 2009; Spolidoro 2002), and therefore, in the
organization of a biobank, any software developed for the
management of data and information will be freely transfer-
able. Such software is also eligible for copyright protection
under International, European and domestic law. On the other
hand, as regards the biobank’s personal data contained in the
database, it will be subject to the stricter rule of Article 16,
paragraph 1, lett. b), of the Italian Data protection law
(Legislative decree no. 196/2003).
According to this provision, in the event of data processing
termination, “the data shall be […] assigned to another data
controller, provided it is intended for processing under terms
that are compatible with the purposes for which the data has
been collected”.
One last clarification concerns the ownership of intellectual
property rights for Italian law. In this respect, it must be
recalled that such rights arising from a patent for invention
or copyright, even where the invention or work has been cre-
ated at the expense of a company, do not belong to the legal
entity, which acquires ownership in a derivative way from the
physical person, who has actually realized the invention or
work. This is a substantial difference with respect to copyright
and patent legislation of the common law IPRs system, where
a company may be originally the owner of intellectual prop-
erty rights.
As regards the topic subject of analysis, we underline the
existence of two different centres of interests. On the one
hand, private companies demand the right to enjoy full pro-
tection of their patented inventions, inclusive of the several
forms of economic exploitation. On the other hand, whether or
not the human genome is a public good is heavily debated,
hence not available for private exploitation. This tension
should be reconciled, considering several benefits that both
public and private actors may enjoy when they look for syn-
ergies. For instance, States may pursue a policy of
commercialising scientific research, whereas private compa-
nies should pay attention to the positive externalities deriving
from a cooperative attitude, such as corporate reputational
gains and increased employee morale. Such an approach, rep-
resented by the creation of public-private partnerships, has
proven to be effective in another sensitive field where patent
law and public interest clash, namely access to essential med-
icines in developing countries (Pusceddu 2014).
Case study n. 2: the CHRIS study: towards a partnership
research/community
“The Cooperative Health Research In South Tyrol (CHRIS)
study is a population-based study with a longitudinal lookout
established in 2011 to investigate the genetic basis of common
chronic conditions associated with human ageing, and their
interaction with life-style and environmental factors in the
general population of South Tyrol” (Pattaro et al. 2015).
All individuals 18 years + and older frommiddle and upper
Vinschgau/Val Venosta are invited to participate to the study.
Ten thousand participated in the study so far. Family partici-
pation is encouraged for complete pedigree reconstruction and
disease inheritance mapping. The goal of the CHRIS study is
to investigate the interaction between the genetic basis of com-
mon chronic conditions with lifestyle and environmental
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factors in the general population. The CHRIS study is focused
on cardiovascular, metabolic, neurological and psychiatric
health. Seventy-three blood and urine parameters are collected
for deep phenotyping and 60 aliquots per participant are col-
lected and preserved in the CHRIS Biobank Samples are ge-
notyped on one million variants with the Illumina®
technology.
The CHRIS study has a longitudinal design plan, with
follow-up starting after 6 years from initial recruitment. In
addition, the CHRIS study is being conducted in the same
geographical area where the MICROS study was previously
carried out in 2002/03 (Pattaro et al. 2015).
The need for follow-ups and re-contact is embedded in the
design of big population studies such as HUNT inNorway, the
Framingham study near Boston etc. The possibility to re-
phenotype or follow-up according to preliminary results to
enrich the dataset and follow new research lines is a desirable
setup, often blocked by demanding and pricy logistics. In
CHRIS, the need to re-contact and establish a stable setup
was clear from the beginning, leading to a strategy aimed at
building long-lasting trust within the community and the
stakeholders. This aim is also reflected in the recruitment strat-
egy and the ELSI approach to the study as well as in the
management of the data and the bioresources.
The communication with the community and the individ-
uals happens in different times along the development of the
study and is especially rich during the recruitment phase.
Embedded in the community on many levels, the CHRIS
study is a public private partnership between non-profit
Academia and the South Tyrolean Health care system. The
recruitment centre is located in the valleys’ reference hospital
of Schlanders/Silandro, the central town of the valley. In each
municipality, the recruitment begins after an informative com-
munication campaign comprising sharing the study concept
with local general practitioners meeting local authorities and
the leaders of local charities and voluntary organizations; an-
nouncing the study to the population through the local media
and holding a town hall public meeting where the study is
officially introduced to the community. This last step guaran-
tees direct interaction and discussion with the public, allowing
the time and opportunity for questions. The active part of the
recruitments foresees a direct invitation by a personal letter
mailed to all 18 + -year-old inhabitants (addresses identified
through publicly available electoral lists). To favour the iden-
tification of genetic variants that might be enriched in single
families, entire families are encouraged to participate. For this
reason, the first invitation is mailed personally to each mem-
ber of the same family at the same time followed by up to two
reminders.
The study is organized to enroll up to 10 participants/day.
After the informed consent procedure, participants undergo
tremor assessment, blood drawing, urine collection, anthropo-
metric measurements, electrocardiographic (ECG) analysis
and blood pressuremeasurement. Finally, participants respond
to a computer assisted personal interview and a computer
aided self-interview.
One week later, participants receive a letter with the com-
plete results of their clinical assessments, including blood,
urine and 10-s ECG results validated by a clinician.
Participants are invited to discuss the results with their GP.
Laboratory life-threatening findings are followed up through
an emergency protocol which, via the study coordinator and
the reference GP, guarantees that the participant is alerted in
the shortest possible time. A senior medical doctor and the
emergency department of Schlanders/Silandro hospital are
covering necessary immediate interventions due to serious
cardiac issues occurring during the ECG or problems arising
during blood drawing according to the study’s emergency
protocols.
The Ethical and legal framework in CHRIs tries to follow a
participant-centric approach.
The CHRIS study was approved by the Ethical Committee
of the Healthcare System of the Autonomous Province of
Bolzano (19 Apr 2011). In addition, the CHRIS study invested
in creating a comprehensive ethical, legal, and social implica-
tion (ELSI) framework aimed at building and ensuring long-
lasting trust and participation.
The study is compliant with current Italian and EU regula-
tion and with the Helsinki Declaration. Privacy and security in
data handling and sharing are strictly enforced and a public
access code regulates how data and samples can be used. Data
and samples are only shared for specific projects and based on
Material and/or Data Transfer Agreement (Pattaro et al. 2015).
The CHRIS governance comprises different levels: an in-
ternal committee which monitors everyday issues (data and
sample access, study management) and three oversight exter-
nal bodies: the ethical board, the scientific board and an eval-
uation committee that evaluates the project’s major changes
and includes stakeholders from the local healthcare system
and study participants. Legal and ethical issues are described
in the Ethical and Legal regulation published on the study
website and include aspects such as return of results, duties
and management of the study, custodianship and benefit-
sharing policies in case of revenues coming from the research,
what happens if the study terminates etc. The whole gover-
nance and the Ethical and Legal regulation are publicly avail-
able and provide a transparent policy for the community and
the stakeholders.
To this end, CHRIS implemented a dynamic consent model
that comprises dynamic information strategy and an IT tool to
support changes over time.
Given that the CHRIS study is designed to be longitudinal,
with use of data and samples that will be extensive and
prolonged over time, an interactive dynamic consent process
for empowering participants’ autonomy and complying with
current regulations was also implemented. Dynamic consent
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includes two important parts: an ongoing information section
and an interactive consent webpage with dynamic options
where individuals could choose between different setups.
Information is provided in different formats to improve
understanding through the use of diverse media that replace
the information sheet. After booking the appointment, partic-
ipants receive at home (by post or email) a detailed informa-
tion brochure (http://www.chrisstudy.it), which includes a
description of the study, images illustrating key concepts in
lay language, and all ethical and legal issues relevant for the
informed consent process. At the study centre, the participant
is invited to watch a 9-min information video (available on the
study webpage) that systematically and fully explains the pro-
ject. The video shows the whole research workflow, outlines
how data and samples are handled, what security measures are
in place and what the risks involved are, and it describes the
participant’s rights and information sources through images
and small animations. After viewing, the participant can ask
questions of the study assistants. While it was not meant to
replace oral communication between participant and study
assistant, the introduction of the video had the effect of short-
ening the time needed for further explanations from about
20 min before its introduction to less than 5 min after its
implementation. A yearly newsletter and updated information
on the webpage complement the ongoing information for
consent.
After the video, electronic consent is filled in online
directly on the personal interactive consent webpage.
The type of consent asked for is broad with regard to
the aim of the study. At the same time, the consent is
layered and provides dynamic options (changeable online
over time) regarding data sharing (international, public
data repositories), return of secondary/unexpected results
(outlining the right to know or the right not to know) and
the permission to use samples and data in case of death or
if the subject loses legal capability.
The data regarding access levels granted by each partici-
pant goes directly into the database and ensures that data can
automatically be filtered for different purposes according to
the participants’ choices.
The dynamic tool can also be used for re-contact, collecting
additional information and re-consent, should this be neces-
sary in the future.
Direct measurements and blood parameters are returned to
participants but no financial compensation or travel cost reim-
bursement is offered to support participation.
Return of unexpected secondary or health threatening re-
sults is provided upon prior explicit participant’s agreement to
be re-contacted. In this case, a multistage consent will take
place so that the participant can be properly re-contacted. In
fact, in the event of genetic clinically relevant findings, an
agreement with the Health Care System genetic counseling
unit ensures that participants are approached by a medical
geneticist, who undertakes proper counseling before results
are tested and confirmed.
Follow-up information flows through the annual newsletter
providing information about new developments and through
the personal webpage in case of important developments that
require direct interaction, such as re-consent.
Access to the bioresource
Sample management, operation, and monitoring instruments
are integrated in a Biobank Information Management System
(BIMS) to ensure security of the biobank collection.
Access to the bioresource is regulated through an access
committee which evaluates research protocols asking to ac-
cess data and samples and based on an access regulation for
internal and external use. The biobank has joined the
Biobanking and Biomolecular Resources Research
Infrastructure (BBMRI) which provides protocols that guar-
antee top-level biological and medical research by promoting
procedure standardization and sample quality. In order to
maximize transparency on the use of samples and data and
for tracking the use of the bioresource, the CHRIS biobank
was assigned a “Bioresource Research Impact Factor” (BRIF)
code (http://www.p3g.org/brif-bioshare-pilot-study):
BRIF6107.
EURAC South Tyrol healthcare partnership
Biomedical research is needed to identify factors that affect
the aging process, which may lead to preventive interventions
for healthy aging with reduction of health care related costs.
For this reason, the CHRIS study was established as a collab-
oration between a research institute (the EURAC Center for
Biomedicine) and the South Tyrolean Health System. Such a
collaboration guarantees that the study operates by actively
interacting with the local population, thus raising awareness
towards a more conscious approach to health. The study is
expected to foster a dynamic cycle among scientists, clinicians
and the whole population, which is to offer reciprocal feed-
back to ultimately improve individuals’ health.
The partnership ensures that the biobank and the Data
Resources, in case EURAC were not able to sustain it further,
are under “public” funding responsibility, ensuring a degree of
sustainability for the bioresource that so much invested in the
community and for the community.
Currently, the genetic epidemiology community is facing
the issue of data sharing on a big scale. Population-based
research is pressured by the dichotomic need on the one hand
to protect data privacy and security, on the other hand, to
maximize the use of stored data and samples, so as to guaran-
tee the maximal benefit to the community. Data harmoniza-
tion, pooling, and sharing are beneficial to scientific research
provided that data security and privacy are guaranteed as new
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tools and governance suggestions have been developed to
foster both aspects, beyond the law (BioSHaRE and
DATASHIELD).
By promoting clear governance rules, third parties’ assess-
ment with regard to data and samples access and, at the same
time, bymaintaining open an individual choice level (dynamic
consent tool), the challenge to adapt to new scientific aspects
and simultaneously comply with upcoming regulations seems
more feasible.
Conclusion
In this paper, we have considered a series of case studies, in
the light of the legal framework of genetics biobanks in Italy.
We have focused on the European and Italian legal frame-
work, analysing in particular the entry into force of the new
EU General Data Protection Regulation (Regulation (EU)
2016/679 of the European Parliament and of the Council of
27 April 2016) and its impact on the Italian legal system. In
addition, we have provided an analysis of the regulation of
gene patenting, balancing the economic value of genetic re-
sources with freedom of scientific research and access to sci-
entific knowledge.
We took into consideration two case studies, dealing re-
spectively with the Sardinia genetics database and the
CHRIS project, which provided specific insights into the gov-
ernance of biobanks’ in Italy. The first one, Shardna, con-
cerned the legal fate of genetic material and data in case of
the biobank’s insolvency, where a static governance did not
take into account some possibilities of flexible adaptability,
and we concluded that there is a need to strike a balance
between private interests surrounding collected genetic mate-
rial and public interest to their proper use and scientific re-
search. In this regard, we concluded that an entirely publicly
owned biobank might guarantee all the interests at stake. As
an alternative, the model of the biotrust will be a particularly
interesting and challenging solution to explore in a civil law
country such as Italy.
Still, the development of science with the compelling need
for re-contact and feedback results is increasingly demanding
an adaptable governance model that does not respond only by
setting regulations. The second case shows how a self-created
governance, supported by tools to enable participatory input
and with the support of dynamic IT-based consent provided
the participants with the ongoing freedom to decide and
change their mind about the fate of data and biosamples, thus
accounting for re-contact needs by researchers and, at the
same time, for the changing nature of research.
These two case studies demonstrated that a civil law coun-
try such as Italy had to provide for flexible legal tools, to
manage all the ethic, legal and societal implications of
biobank regulation and governance. Beside, although the
topics and the case studies we took into consideration are
different from each other, they all seem to point in one direc-
tion, urging the need for cooperation and synergies between
public and private actors, law and soft provisions. Public-
private partnership might respond to the converging inter-
ests—public and private, economic and scientific research
oriented—and to the need for flexibility of regulation of these
complex objects, which are the biological samples and the
precious information they contain.
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